1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Strategy

Cough And Cold Symptoms, Some Coming From Omicron, Sound Like Seasonal Rebound To Perrigo

Consumer Health Product Firm Notes Potential Sales Impact From Russia’s Invasion Of Ukraine

 
• By Malcolm Spicer

Sales growth generated in October-December period and growing incidences of flu and cough/cold symptoms are harbingers for Perrigo in 2022. Sales during January and February in Russia and Ukraine tracked with $10m to $15m operating income firm anticipates there for 2022, “but it's really too early to estimate the potential full-year impact,” CEO Murray Kessler says.

• Source: Alamy

Every cough, sniffle or sneeze by consumers doesn’t directly link to sales of Perrigo Company PLC’s cough/cold lines, but the OTC private label/store brand giant makes clear that the return of more normal seasonal viruses is a key sales driver.

And the recent recall of a leading national infant formula brand correlates to higher sales of Perrigo’s formula products, which already were among the firm’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.